BMO Capital Markets upgraded shares of Abbott Laboratories (NYSE:ABT) from a market perform rating to an outperform rating in a report issued on Tuesday, Marketbeat reports. They currently have $65.00 price target on the healthcare product maker’s stock, up from their previous price target of $58.00.

A number of other analysts also recently commented on the company. Zacks Investment Research raised Abbott Laboratories from a hold rating to a buy rating and set a $61.00 price objective on the stock in a research note on Tuesday, October 31st. Royal Bank of Canada reissued a buy rating and issued a $55.00 price objective on shares of Abbott Laboratories in a research note on Tuesday, October 3rd. Jefferies Group reissued a buy rating and issued a $65.00 price objective on shares of Abbott Laboratories in a research note on Thursday, October 19th. Bank of America reissued a buy rating and issued a $60.00 price objective (up previously from $56.00) on shares of Abbott Laboratories in a research note on Wednesday, October 4th. Finally, Citigroup reissued a neutral rating on shares of Abbott Laboratories in a research note on Thursday, October 19th. Seven equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $57.56.

Abbott Laboratories (NYSE:ABT) opened at $55.50 on Tuesday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.26 and a current ratio of 2.69. Abbott Laboratories has a 12-month low of $37.90 and a 12-month high of $56.69. The stock has a market capitalization of $97,960.00, a price-to-earnings ratio of 22.85, a price-to-earnings-growth ratio of 2.06 and a beta of 1.55.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.01. Abbott Laboratories had a return on equity of 13.98% and a net margin of 8.37%. The company had revenue of $6.83 billion during the quarter, compared to analyst estimates of $6.72 billion. During the same quarter in the previous year, the firm posted $0.59 EPS. The firm’s quarterly revenue was up 28.8% on a year-over-year basis. sell-side analysts expect that Abbott Laboratories will post 2.49 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be given a dividend of $0.28 per share. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.27. This represents a $1.12 dividend on an annualized basis and a dividend yield of 2.02%. Abbott Laboratories’s payout ratio is 87.60%.

In related news, insider Sharon J. Bracken sold 2,188 shares of the company’s stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $56.12, for a total transaction of $122,790.56. Following the transaction, the insider now directly owns 25,618 shares of the company’s stock, valued at $1,437,682.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jaime Contreras sold 52,700 shares of the company’s stock in a transaction on Friday, September 22nd. The shares were sold at an average price of $51.97, for a total value of $2,738,819.00. Following the transaction, the insider now directly owns 58,739 shares in the company, valued at $3,052,665.83. The disclosure for this sale can be found here. Insiders have sold 616,332 shares of company stock worth $33,579,226 over the last ninety days. 0.76% of the stock is owned by insiders.

A number of large investors have recently bought and sold shares of ABT. DE Burlo Group Inc. purchased a new position in Abbott Laboratories in the first quarter valued at about $213,000. Thomaspartners Inc. grew its stake in Abbott Laboratories by 10.3% in the first quarter. Thomaspartners Inc. now owns 5,099,993 shares of the healthcare product maker’s stock valued at $226,491,000 after purchasing an additional 475,033 shares in the last quarter. Karp Capital Management Corp purchased a new position in Abbott Laboratories in the first quarter valued at about $32,885,000. First Foundation Advisors grew its stake in Abbott Laboratories by 2.1% in the first quarter. First Foundation Advisors now owns 13,588 shares of the healthcare product maker’s stock valued at $603,000 after purchasing an additional 283 shares in the last quarter. Finally, Baker Chad R purchased a new position in Abbott Laboratories in the first quarter valued at about $3,220,000. 71.32% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This news story was posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/abbott-laboratories-abt-upgraded-to-outperform-by-bmo-capital-markets/1767071.html.

Abbott Laboratories Company Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Analyst Recommendations for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.